Center-Authored Papers

Filters: Author is Goy, Andre  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C-J, Williams MP, Shaffer AL, Gerecitano J et al..  2015.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.. Nature medicine. Abstract
S
Sehn LH, Goy A, Offner FC, Martinelli G, Caballero DM, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE et al..  2015.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(30):3467-3474. Abstract
K
Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G et al..  2016.  FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.. Leukemia & lymphoma. :1-10. Abstract
H
Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM et al..  2013.  CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies.. Journal of clinical pharmacology. 53(8):866-77. Abstract
G
Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A.  2014.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.. Investigational new drugs. 32(6):1213-25. Abstract
C
Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, Gopal AK.  2015.  A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma.. Clinical lymphoma, myeloma & leukemia. Abstract